Ventyx Biosciences, Inc. is a Pharmaceuticals company based in the United States, specializing in developing innovative treatments for patients with inflammatory diseases and autoimmune disorders. Their ESG score is 29.1, indicating a medium risk assessment. The company is focused on creating small-molecule product candidates, with VTX958 being a notable oral TYK2 inhibitor.